15 completed, 4 terminated, 1 active not recruiting, 1 unknown. 21 Phase 1, 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 21 | Completed 15, Terminated 4, Active not recruiting 1, Unknown 1 |
| Phase 2 | 9 | Completed 5, Terminated 2, Active not recruiting 1, Unknown 1 |
Follow Array BioPharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab Phase Ib ARRY-614 + nivolumab, Phase Ib ARRY-614 + nivolumab+ipilimumab, Phase II ARRY-614 + nivolumab - Renal Cell Carcinoma, Melanoma | Phase 1 / Phase 2 | Active not recruiting | Dan Zandberg | 70 | 2020-06-11 | 2025-11-06 |
| Lorlatinib Combinations in Lung Cancer Lorlatinib, Crizotinib, Binimetinib - Lung Cancer, Anaplastic Lymphoma Kinase Gene Translocation | Phase 1 / Phase 2 | Unknown | Massachusetts General Hospital | 96 | 2020-05-01 | 2021-03-10 |
| Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer Binimetinib, Brigatinib - ALK Gene Rearrangement, Lung Non-Small Cell Carcinoma | Phase 1 | Terminated | University of California, San Francisco | 3 | 2020-02-25 | 2022-10-17 |
| A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers Binimetinib, Encorafenib - Advanced BRAF Mutant Cancers | Phase 1 / Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 17 | 2019-02-14 | 2024-10-21 |
| Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651) Pembrolizumab, Binimetinib, Oxaliplatin - Metastatic Colorectal Cancer | Phase 1 | Completed | Merck Sharp & Dohme LLC | 116 | 2018-02-16 | 2024-11-21 |
| Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer Binimetinib, Palbociclib - Lung Cancer | Phase 1 | Completed | Dana-Farber Cancer Institute | 34 | 2017-05-31 | 2026-02-12 |
| A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST) MEK162, Pexidartinib - Gastrointestinal Stromal Tumor (GIST) | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 3 | 2017-04-15 | 2021-04-30 |
| Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients Filanesib, pomalidomide and dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Completed | PETHEMA Foundation | 47 | 2015-09-01 | 2022-07-27 |
| An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T) MEK-162, Nilotinib, Questionnaires - Leukemia | Phase 1 | Terminated | M.D. Anderson Cancer Center | 1 | 2015-03-11 | 2020-02-12 |
| Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations WNT974, LGX818, Cetuximab - Metastatic Colorectal Cancer | Phase 1 / Phase 2 | Completed | Array BioPharma | 20 | 2014-12-01 | 2017-10-09 |
| MEK and MET Inhibition in Colorectal Cancer PF-02341066, PD-0325901, Binimetinib - Solid Tumor, Colorectal Cancer | Phase 1 | Completed | University of Oxford | 82 | 2014-11-01 | 2021-07-13 |
| MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy MEK 162 - Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 19 | 2014-08-27 | 2021-04-20 |
| MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer MEK inhibitor MEK162, leucovorin calcium, fluorouracil - Recurrent Colon Cancer, Recurrent Rectal Cancer | Phase 1 | Completed | City of Hope Medical Center | 26 | 2014-07-16 | 2026-10-19 |
| A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation MEK162, Erlotinib - Lung Cancer, Non-Small Cell Lung Cancer | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 43 | 2013-12-30 | 2023-01-19 |
| ARRY-380 + Trastuzuamab for Breast w/ Brain Mets ARRY-380 Twice Daily Dosage, ARRY-380 Once Daily, Trastuzumab - Brain Metastases From HER2 and Breast Cancer, Advanced HER2-positive Breast Cancer | Phase 1 | Completed | Dana-Farber Cancer Institute | 41 | 2013-08-01 | 2024-11-06 |
| Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma. LEE011, LGX818 - Locally Advanced Metastatic BRAF Mutant Melanoma | Phase 1 / Phase 2 | Terminated | Array BioPharma | 28 | 2013-07-01 | 2016-09-13 |
| First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma Gemcitabine, Cisplatin, MEK162 - Advanced Biliary Tract Carcinoma | Phase 1 / Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 42 | 2013-04-01 | 2020-11-17 |
| A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors BYL719, MEK162 - Advanced and Selected Solid Tumors, AML | Phase 1 | Completed | Array BioPharma | 139 | 2012-03-01 | 2017-10-02 |
| A Safety Study of ARRY-403 in Patients With Type 2 Diabetes ARRY-403, glucokinase activator; oral, Placebo; oral - Type 2 Diabetes | Phase 1 | Completed | Array BioPharma | 41 | 2009-03-01 | 2012-08-30 |
| A Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic Cancer ARRY-334543, EGFR/ErbB2 inhibitor; oral, Gemcitabine, nucleoside analogue; intravenous - Advanced Cancer, Pancreatic Cancer | Phase 1 / Phase 2 | Completed | Array BioPharma | 20 | 2009-03-01 | 2012-10-04 |
Showing 20 of 21. Sign in to see all of them.
Lung Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (3) · Colorectal Neoplasms (3) · Leukemia (2) · Melanoma (2) · Recurrence (2) · Blast Crisis (1) · Breast Neoplasms (1) · Carcinoma, Renal Cell (1) · Colonic Neoplasms (1) · Diabetes Mellitus, Type 2 (1) · Disease Progression (1) · Gastrointestinal Stromal Tumors (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Myeloid, Chronic-Phase (1)
binimetinib (12) · encorafenib (3) · Crizotinib (2) · Fluorouracil (2) · Gemcitabine (2) · Leucovorin (2) · Oxaliplatin (2) · ARRY-334543 (1) · ARRY-403 (1) · Alpelisib (1) · Cetuximab (1) · Cisplatin (1) · Dexamethasone (1) · ErbB Receptors (1) · Erlotinib Hydrochloride (1)
United States (19) · Canada (4) · Australia (3) · Spain (3) · France (2) · Italy (2) · Netherlands (2) · United Kingdom (2) · Belgium (1) · Israel (1) · Singapore (1) · Switzerland (1)
Collin Blakely, MD, PhD (1) · Dan Zandberg, MD (1) · Farhad Ravandi-Kashani, MD (1) · Geoffrey Shapiro, MD, PhD (1) · Ghassan Abou-Alfa, MD (1) · Ibiayi Dagogo-Jack, MD (1) · Jhanelle Gray, M.D. (1) · Mark R Middleton (1) · Marwan Fakih (1) · Nancy Lin, MD (1) · Naval Daver, MD (1) · Ocio Enrique, DR (1)
PMID 10564685, PMID 15902208, PMID 15958804, PMID 17975015, PMID 18032762, PMID 18032763, PMID 19901123, PMID 31213500, PMID 32461105, PMID 32501528, PMID 35385748, PMID 36811382, PMID 37499521, PMID 38653648, PMID 38762348, PMID 40578933, PMID 8797771